Please login to the form below

Not currently logged in
Email:
Password:

ImmunoGen

This page shows the latest ImmunoGen news and features for those working in and with pharma, biotech and healthcare.

Roche submits Kadcyla for FDA Real-Time review

Roche submits Kadcyla for FDA Real-Time review

It combines two anti-cancer properties, trastuzumab (the active ingredient in Herceptin) and the chemotherapy agent DM1, which it licensed from biotech ImmunoGen.

Latest news

More from news
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    250+. Immunogen (US). Jazz (IE, US). Collaboration and option. Phase I haematology-related antibody-drug conjugate plus 2 other projects.

  • Pharma deals in April 2015 Pharma deals in April 2015

    Termination. As part of its ongoing re-prioritisation and trimming of its oncology pipeline and correspondingly downsizing and reorganising the R&D teams, Sanofi is terminating its agreement with ImmunoGen and

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    265. Immunogen / Takeda. Licence and collaboration option. Antibody-drug conjugate (ADC) technology to develop 2 anticancer products option on 3rd.

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    240.5. ImmunoGen / Novartis. Licence. ADC technology - extension of 2010 agreement.

  • Pharma deals during October 2013 Pharma deals during October 2013

    This month ImmunoGen and Novartis announced a second licence under their 2010 agreement giving Novartis rights to the biotech's ADC technology to develop anticancer therapeutics to an undisclosed target. ... ImmunoGen could receive around $200m in

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes.

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    Eric Guempel joins from Merck Serono. ImmunoGen has appointed Eric Guempel as the company's first VP of product strategy and programme management. ... Dr Charles Morris explained the creation of Guempel's new role. “Eric joins ImmunoGen in a new

  • AVEO's financial head joins ImmunoGen AVEO's financial head joins ImmunoGen

    David Johnston appointed chief financial officer. David Johnston has left his role as chief financial officer of AVEO Pharmaceuticals to join ImmunoGen in the same role. ... I am delighted to have Dave join ImmunoGen,” commented ImmunoGen's CEO Daniel

  • Charles Morris appointed chief development officer at ImmunoGen Charles Morris appointed chief development officer at ImmunoGen

    ImmunoGen said it also expects to advance a fourth compound into clinic studies in 2013. ... We are excited to have Charlie joining ImmunoGen at this important time in our transition to being a product development company.".

More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...

Latest intelligence

PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing
Social media - friend or foe?...

Infographics